Business Description
BioVie Inc. is a US-based medical research company focused on developing new treatments for brain diseases and serious liver conditions. Its two main drug candidates are BIV201, currently in Phase 2 trials for fluid buildup caused by liver cirrhosis, and NE3107, which is being tested in Phase 3 trials for Alzheimer's disease and in Phase 2 trials for Parkinson's disease and long COVID. Founded in 2013 and headquartered in Carson City, Nevada, the company was previously called NanoAntibiotics Inc. before rebranding in 2016.
